Alcon Inc. (FRA:2U3)
Germany · Delayed Price · Currency is EUR | Market Cap | 33.48B |
| Revenue (ttm) | 8.68B |
| Net Income (ttm) | 892.36M |
| Shares Out | n/a |
| EPS (ttm) | 1.79 |
| PE Ratio | 37.52 |
| Forward PE | 24.03 |
| Dividend | 0.30 (0.44%) |
| Ex-Dividend Date | May 13, 2025 |
| Volume | 11,652 |
| Average Volume | 190 |
| Open | 52.91 |
| Previous Close | 52.88 |
| Day's Range | 52.91 - 54.40 |
| 52-Week Range | 54.07 - 85.74 |
| Beta | n/a |
| RSI | 54.16 |
| Earnings Date | Feb 26, 2026 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial numbers in USD Financial StatementsNews
Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
Expresses Disappointment in the Board's and Management's Continued Pursuit of Ill-advised Deal CHARLOTTE, N.C. , Dec. 17, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareh...
Alcon (ALC) Acquisition of STAAR Surgical Faces Strong Opposition
Alcon (ALC) Acquisition of STAAR Surgical Faces Strong Opposition
Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
Alcon (ALC) Merger Proposal Faces Crucial Vote by STAAR Shareholders
Alcon (ALC) Merger Proposal Faces Crucial Vote by STAAR Shareholders
STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today issued the following open letter to ST...
STAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Yunqi Capital Opposes Alcon's Acquisition Proposal for STAAR Surgical (ALC)
Yunqi Capital Opposes Alcon's Acquisition Proposal for STAAR Surgical (ALC)
Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Alcon (ALC) Replaced on Needham's Conviction List
Alcon (ALC) Replaced on Needham's Conviction List
Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on a report published by Institutional Shareholder Services Inc. (“ISS”), an independent proxy advisory firm, which re...
Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on a report published by Institutional Shareholder Services Inc. (“ISS”), an independent pr...
STAAR Surgical (STAA) Gains as ISS Backs Alcon's Improved Offer
STAAR Surgical (STAA) Gains as ISS Backs Alcon's Improved Offer
STAAR Surgical gains as proxy adviser ISS supports revised Alcon deal
STAAR Surgical shares jump after ISS backs Alcon's $30.75 buyout offer. Discover key shareholder moves and what this means ahead of the Dec. 19 vote.
Staar Surgical Endorses Alcon (ALC) Merger, Backed by New ISS Report
Staar Surgical Endorses Alcon (ALC) Merger, Backed by New ISS Report
STAAR Surgical (STAA) Faces Investor Pushback on Alcon Offer
STAAR Surgical (STAA) Faces Investor Pushback on Alcon Offer
STAAR Surgical falls as proxy adviser recommends against revised Alcon deal
Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, ha...
Alcon (ALC) Sees Downgrade, Shares Drop 1.6%
Alcon (ALC) Sees Downgrade, Shares Drop 1.6%
Alcon (ALC) Faces Downgrade Amid Earnings Concerns
Alcon (ALC) Faces Downgrade Amid Earnings Concerns
Alcon draws double downgrade at BofA on earnings growth risk
Alcon Just Got Hit With Its First Bearish Call Since August
Alcon Just Got Hit With Its First Bearish Call Since August
Alcon (ALC) Involved in STAAR's Assertive Response to Merger Misconceptions
Alcon (ALC) Involved in STAAR's Assertive Response to Merger Misconceptions
STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Concerns Arise Over Alcon's Proposed Acquisition of Staar Surgical (ALC)
Concerns Arise Over Alcon's Proposed Acquisition of Staar Surgical (ALC)
Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today reacted to the proxy statement supplement filed by STAAR Surgical Company (“STAAR” or the “Company”) ...